Search research articles
Contact Us
Filters
Showing results (111-120 of 301) with videos related to
Page
of 31
Sort By:
Blood Cancer Journal
|
January 4, 2023
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Hira Mian, Arleigh McCurdy, Smith Giri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
Clément Bailly, Thomas Carlier, Bastien Jamet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Prognostic significance of copy-number alterations in multiple myeloma
Hervé Avet-Loiseau, Cheng Li, Florence Magrangeas, et al.
Blood
|
August 23, 2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
Martine Gardembas, Philippe Rousselot, Michel Tulliez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2002
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
Hans D Menssen, Adriana Sakalová, Aurélie Fontana, et al.
Hematological Oncology
|
June 2, 2022
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Facon, Philippe Moreau, Thomas G Martin, et al.
Haematologica
|
September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
Meletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Plos One
|
June 7, 2013
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model
Haneen Nur, Karel Fostier, Sandrine Aspeslagh, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
August 22, 2002
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM)
Ibrahim Yakoub-Agha, Michel Attal, Charles Dumontet, et al.
Leukemia & Lymphoma
|
April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Katja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.
Page
of 31
Search research articles
Search
Showing results (111-120 of 301) with videos related to
Sort By:
Page
of 31
Blood Cancer Journal
|
January 4, 2023
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review
Hira Mian, Arleigh McCurdy, Smith Giri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study
Clément Bailly, Thomas Carlier, Bastien Jamet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Prognostic significance of copy-number alterations in multiple myeloma
Hervé Avet-Loiseau, Cheng Li, Florence Magrangeas, et al.
Blood
|
August 23, 2003
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
Martine Gardembas, Philippe Rousselot, Michel Tulliez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2002
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma
Hans D Menssen, Adriana Sakalová, Aurélie Fontana, et al.
Hematological Oncology
|
June 2, 2022
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
Thierry Facon, Philippe Moreau, Thomas G Martin, et al.
Haematologica
|
September 28, 2014
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
Meletios A Dimopoulos, Robert Z Orlowski, Thierry Facon, et al.
Plos One
|
June 7, 2013
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model
Haneen Nur, Karel Fostier, Sandrine Aspeslagh, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
August 22, 2002
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM)
Ibrahim Yakoub-Agha, Michel Attal, Charles Dumontet, et al.
Leukemia & Lymphoma
|
April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
Katja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.
Page
of 31